| Description |
Atopic dermatitis (AD) is a common chronic skin disease. Severe forms of AD are difficult to manage only with local preparations, therefore, at a certain stage of the disease, systemic therapy is often needed. Non-specific (traditional) immunosuppressants used in AD include cyclosporine, methotrexate, azathioprine, mycophenolate mofetil and corticosteroids. Our understanding of AD pathophysiology expands as research advances, new treatments can inhibit specific cytokines, chemokines, and/or receptors. Currently, for the treatment of moderate to severe atopic dermatitis (AD), there are two groups of modern systemic therapies with a total of five drugs in the Czech Republic: biological therapy (dupilumab, tralokinumab) and "small molecules" (abrocitinib, baricitinib, upadacitinib ). In addition to genetic and biological markers, modern AD therapy also takes into account phenotypic features, it should be patient-oriented and chosen individually. When choosing a preparation, one must consider the positive therapeutic effects, spectrum of potential side effects, safety profile, comorbidities, onset of effect, patient preference (oral or injectable form of the drug) and, last but not least, the price and coverage of the drug by insurance companies.
|